A5029231746- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Gyrotron and Vacuum Electronics Research
- Chemical Reactions and Isotopes
- Radiopharmaceutical Chemistry and Applications
- HER2/EGFR in Cancer Research
- Colorectal and Anal Carcinomas
- Metastasis and carcinoma case studies
Instituto de Gastroenterología
2012-2022
Instituto Alexander Fleming
2006
Neuroendocrine tumors (NET) include a spectrum of malignancies arising from neuroendocrine cells throughout the body. The objective this clinical investigation retrospectively and prospectively collected data was to describe prevalence, demographic data, symptoms methods diagnosis NET treatment long-term follow-up patients with NET. Data were provided by participating centers assessed for consistency internal reviewers. All cases centrally evaluated (when necessary) pathologists in our...
14142 Background: PDNEC-Small cell (OMS Clasification, grade III)of the GI tract are rare diseases. Small cel represent 0,1% to 1% of all malignancies, and included in group PDNEC but: Do these behave biologically respond treatment same way? Trying elucidate this matter, we performed a retrospective analysis our pts. with PDNEC. Methods: A database search was done. from 1997 2005 found 31 PDNEC/Small Tract treated Centers. review clinical records special interest response rate overall...
255 Background: Grade 2 (G2) Neuroendocrine tumors (NETs), of the digestive tract is a heterogeneous group tumors. Several treatment options including chemotherapy and target therapy are available, but there lack prospective trials assessing role pronostic factors in this population. Aim(s): to analyze prognostic clinical characteristics population patients with G2 GEP-NETs. To determine ki 67 stratification Methods: Study was obtained from our database (Argentum Group). Survival estimated...
e15188 Background: Grade 2 (G2) Neuroendocrine tumors (NETs), of the digestive tract is a heterogeneous group tumors. Several treatment options including chemotherapy and target therapy are available, but there lack prospective trials assessing role pronostic factors in this population. Aim(s): to analyze prognostic clinical characteristics population patients with G2 GEP-NETs. To determine ki 67 stratification Methods: Study was obtained from our database (Argentum Group). Survival...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
e14533 Background: Midgut carcinoids (CTs) have a rising incidence ≈ 1/100,000. Few studies investigated risk factors for their occurrence, reporting possible role of family history (FH) CTs and colorectal cancer (CRC), smoking. Our aim is to identify the occurrence in prospectively evaluated cohort. Methods: Multicentre case- control (C-C) study. Patients with diagnosis CTs, without familial syndromes. Controls nonneoplastic/nonchronic disorders. All interviewed on demographics potential...
e14588 Background: Digestive endocrine tumors (dETs) are in 40%-60% of cases advanced at diagnosis. TNM staging system includes stage IV all pts with metastases (METs), but its prognostic role according to METs site is unknown. Our aim was evaluate accuracy predict clinical outcome dETs. Methods: Retrospective analysis single-center dETs database. Inclusion sporadic pancreatic ETs (PETs) and intestinal carcinoids (CTs) divided in: group 1, limited the liver ≤ 5 METs; 2, > 3, extra-abdominal...
e14598 Background: Somatostatin receptor expression (SSTR), mainly subtypes 2 and 5, is a feature of well differentiated GEP-NETs. Such has prognostic predictive value for the use somatostatin analogs.Ki 67, present during cycle phases (G1, S, G2 y M) nuclear antigen associated with cell proliferation. The correlation between both clinical pathological factors under active investigation in patients Methods: An analysis including 100 database Argentum Group was performed. Consecutive were...

 Los tumores neuroendocrinos G2 (TNE) del tracto digestivo son un grupo heterogéneo de con múltiples opciones tratamiento, pero los ensayos prospectivos que evalúan el papel factores predictivos en estos pacientes escasos. El objetivo fue analizar pronósticos y características clínicas una población G2-TNE determinar Ki-67 la estratificación G2. La supervivencia se estimó mediante método Kaplan-Meier cuartiles compararon prueba log-rank. valor para discriminar mortalidad...